In randomized studies researchers may be interested in the effect of treatment assignment on a time-to-event outcome that only exists in a subset selected after randomization. For example, in preventative HIV vaccine trials, it is of interest to determine whether randomization to vaccine affects the time from infection diagnosis until initiation of antiretroviral therapy. Earlier work assessed the effect of treatment on outcome among the principal stratum of individuals who would have been selected regardless of treatment assignment. These studies assumed monotonicity, that one of the principal strata was empty (eg, every person infected in the vaccine arm would have been infected if randomized to placebo). Here we present a sensitivity analysis approach for relaxing monotonicity with a time-to-event outcome. We also consider scenarios where selection is unknown for some subjects because of non-informative censoring (e.g., infection status k years after randomization is unknown for some because of staggered study entry). We illustrate our method using data from an HIV vaccine trial.
Introduction
In randomized controlled trials, researchers are often interested in evaluating the effect of treatment in a subgroup of individuals selected post-randomization. For example, in HIV vaccine trials of T cell based vaccines, it is of primary interest to assess the effect of vaccination on outcomes only measured in those who get infected (eg, time from infection diagnosis to initiation of antiretroviral therapy), as candidate T cell based vaccines are specifically designed to control rather than prevent infection (Mehrotra, Li, and Gilbert 2006; Graham 2002; Buchbinder et al. 2008; www.hvtn.org) .
When an analysis selects on a post-randomization variable such as infection, selection bias could arise. Even though treatment is randomly assigned, subjects selected based on a post-randomization variable are not randomly selected. Subject characteristics of those selected could differ between treatment arms if treatment assignment influences selection (Rosenbaum 1984 ).
In such situations, Frangakis and Rubin (2002) proposed focusing inference on the subgroup of individuals whose post-randomization selection variable is the same regardless of treatment assignment. These subgroups have been coined principal strata. For example, in the HIV vaccine studies, researchers have estimated the effect of vaccination on post-infection outcomes among those who would have been infected regardless of treatment assignment (Hudgens, Hoering, and Self 2003 (HHS) ; Gilbert, Bosch, and Hudgens 2003 (GBH) ).
Unfortunately, principal stratum membership is not known because participants are only assigned to one treatment. Therefore, assumptions and/or sensitivity analyses are required to estimate causal effects within principal strata. HHS and GBH assumed monotonicity -that every person infected in the vaccine arm would have been infected had they been randomized to placebo. They then performed a sensitivity analysis examining results under different assumptions regarding the probability of infection if assigned vaccine given infection under placebo and the outcome. Shepherd, Gilbert, and Lumley (2007) (SGL) extended HHS and GBH to the situation where the outcome is the possibly right-censored time from selection to some later event. Again, SGL assumed monotonicity.
Monotonicity is a strong assumption -that one of the principal strata is empty. This assumption is never completely verifiable because participants are only assigned a single treatment. One could test the null hypothesis that the probability of selection in a treatment arm (eg, vaccine) is less than or equal to the probability of selection in the other arm (eg, placebo); if this null hypothesis is rejected (possibly within a subgroup defined by baseline covariates) then monotonicity is rejected. However, the rate of selection could be lower for treatment in all subgroups, yet monotonicity may still be violated. In the context of HIV vaccine trials, results from a recent trial also make it more difficult to assume monotonicity in future vaccine studies, as the risk of HIV-infection appeared higher in the vaccine arm than placebo within certain study subgroups (Buchbinder et al. 2008) . Therefore, it is important to have methods for relaxing monotonicity.
Large sample bounds without assuming monotonicity were developed by Jemiai (2005) and Zhang and Rubin (2003) for the average causal effect in the principal stratum of those individuals who would have been selected regardless of treatment assignment. These bounds are important, but represent extremes which are typically not plausible; and, as shown by Jemiai (2005) , in many cases these bounds are non-informative, as they are simply equivalent to plus or minus the difference between the minimum and maximum of the support of the outcome of interest. Jemiai and Rotnitzky developed sensitivity analysis methods which relax the monotonicity assumption (Jemiai 2005) . These methods were applied by Shepherd, Redman, and Ankerst (2008) to an analysis investigating the effect of treatment (finasteride) on the severity of prostate cancer among men who would have had cancer regardless of treatment assignment.
In this manuscript, we develop methods that relax monotonicity and estimate the effect of treatment on a right-censored outcome in a subset of individuals who would be selected for inclusion regardless of their treatment assignment. These methods are an extension of Jemiai (2005) (extending to a possibly right-censored outcome) and SGL (extending to relax monotonicity). In section 2 we specify our notation and assumptions. Section 3 addresses estimation and inference, and section 4 considers specific scenarios which may arise in practice where either the number of selection events is fixed by the trial design or the selection event status of some participants is unknown because of censoring. Section 5 contains a simulation study to investigate finite sample behavior, section 6 applies these methods to data from an HIV vaccine trial, and section 7 discusses results.
Notation, Causal Estimand, and Assumptions
Consider a study in which N subjects, independently and randomly selected from a given population of interest, are randomized to one of two treatments, Z i = 0 or Z i = 1, for i = 1, · · · , N . Define S i as a post-randomization selection variable where S i = 1 implies an individual is selected, otherwise S i = 0. For instance, in the HIV vaccine trial example, S i = 1 if infected, S i = 0 otherwise. Let T i be the time from selection until some event for subject i, and define C i as the time from selection until censoring. If S i = 1, we observe
otherwise they are assigned the value * .
To define the estimand of interest, we use potential outcomes/counterfactuals (Neyman 1923 , Rubin 1978 , Robins 1986 ). Specifically, define S i (0) to be the selection indicator if, possibly contrary to fact, Z i = 0. Define S i (1) to be the selection indicator if Z i = 1.
Similarly, define T i (0) to be the time-to-event outcome if Z i = 0 and T i (1) to be the timeto-event outcome if Z i = 1. The potential outcomes C i (z), Y i (z), and δ i (z) are similarly defined for z = 0, 1. This notation implicitly assumes that the potential outcomes of each trial participant are not influenced by the treatment assignments of other participants, an assumption known as no interference (Cox, 1958) .
Assuming the study participants make up a random sample from a large population of interest, the outcomes (
, and similarly the ob-
The assumptions of no interference and consistency constitute the stable unit treatment value assumption (SUTVA) (Rubin 1978) .
Random assignment of treatment ensures that
Here, for random variables A, B and C, A ⊥ ⊥ B | C indicates conditional independence of A and B given C. We will also assume independent censoring:
The four basic principal strata (Frangakis and Rubin 2002) can be defined in terms of the counterfactual pair (S (0) , S (1)): (0,0), (0,1), (1,0), (1,1). For a subject i who is in the principal stratum defined by (S(0), S(1)) = (1, 1), a causal effect on his/her time-to-event outcome is some measure of discrepancy between T i (0) and T i (1). Following SGL, we focus on the "survival" causal effect in the stratum (S(0), S(1)) = (1, 1):
In order to estimate SCE(t), in earlier work we made the following additional assumptions:
A.1: Monotonicity:
is fixed and known, G 0 (·) is a known cdf, α 0 is an unknown parameter, and for each β 0 , h 0 (t; β 0 ) is a known function of t.
A.1, together with SUTVA, (1), and (2), identify (Scharfstein, Rotnitzky, and Robins 1999; GBH) . SGL specified w 0 (t; β 0 ) with the expit function,
where τ is some number less than or equal to the maximum length of follow-up. The expit function form for w 0 (·) was originally used by GBH. With w 0 (·) specified with the expit function, exp(β 0 ) has an odds ratio interpretation. Once β 0 is fixed, α 0 is identified by recognizing that w 0 (t; β 0 )dF 0 (t) = P r(S = 1|Z = 1)/P r(S = 1|Z = 0). SGL slightly modified w 0 (·) (included min(t, τ ) as opposed to simply t) in order to make w 0 (·) constant for t > τ . With time-to-event data, follow-up is typically restricted so that F 0 (t) cannot be estimated nonparametrically for large t; hence, SGL's modification permitted estimation of α 0 without assuming a parametric distribution for F 0 (t).
In this manuscript we relax assumption A.1 following an approach originally proposed by Jemiai 2005. Instead of assuming A.1, we will assume B.1 and the following:
is fixed and known, G 1 (·) is a known cdf, α 1 is an unknown parameter, and for each β 1 , h 1 (t; β 1 ) is a known function of t.
, where ψ is fixed and known.
Assumption B.2 is analagous to B.1, and similar to (3), we will model w 1 (·) with an expit function,
treating β 1 as a sensitivity parameter. Assumption B.3 specifies the joint distribution of (S(0), S (1)). The parameter ψ is not known, but will be treated as a sensitivity parameter and varied over a range of plausible values. ψ can be interpreted as the log odds ratio of selection under randomization Z = 1 for those selected versus those not selected under
For ease of interpretation and presentation, we will additionally define the parameters
, and φ = P (S(0) = 1|S(1) = 1), which will be helpful later in the paper. Instead of specifying the log-odds ratio sensitivity parameter ψ, one could specify π or φ. Specifying any of these (among other) parameters, together with the marginal probabilities p 0 and p 1 (which are identifiable from the observed data), specify the joint distribution of (S(0), S (1) for z = 0, 1 can be interpreted from Figure 1 as the proportion of the shaded curve less than or equal to t = 2. SCE(2) is simply the difference between these cdfs.
[ Figure 
Estimation
Under B.1-B.3,
where with unspecified limits of integration denotes
. Note that for z = 0, 1,
We use this result to estimate α z once the sensitivity parameters β z and π have been specified.
Specifically, P (S = 1|Z = z) is consistently estimated byp z = n z /N z , where N z and n z are the number of subjects randomized and selected (S i = 1), respectively, with Z i = z. For given π, β 0 , β 1 , we can then estimate α z using (6), by plugging in the Kaplan-Meier estimates for It should be recognized again that π is constrained to be within [max(0, p 0 + p 1 − 1), min(p 0 , p 1 )] and that this estimation procedure will have problems if π is outside the range
, there is no value of α 1 that will solve w 1 (t; α 1 , β 1 )dF 1 (t)) = πN 1 /n 1 . An ad hoc fix in this situation is to set π = n 1 /N 1 and perform the analysis.
Alternatively, one could choose a range for plausible values of π (or equivalently φ) based on the estimated valuesp z . However, this is a little unsettling as π is treated as fixed and known in the analysis. We will follow Jemiai (2005) and avoid this problem by specifying the unrestrained parameter ψ and then recognizing that
Therefore, for a given ψ, π(ψ, p 0 , p 1 ) will be estimated as π(ψ,p 0 ,p 1 ). If results are presented using the sensitivity parameter φ instead of ψ (as in the Section 6), then it should be recognized that φ must satisfy π(ψ,p 0 ,p 1 )/p 1 .
Our estimator for SCE(t) is consistent and asymptotically normal, following the results of SGL. Confidence intervals for SCE(t)
can therefore be computed using bootstrap techniques, sampling with replacement N records from O i (described in more detail in section 5).
Additional Considerations

Fixed number of selection events
In some studies, the trial continues until a pre-specified number of total events are accrued (i.e., until S i = n, where n is fixed before the trial begins). For example, some HIV vaccine trials continue until a certain number of infections are observed. In this situation, estimation of SCE(t) is identical, although variance estimates may need to be adjusted.
A slight variation of the bootstrap confidence intervals is sufficient: Instead of sampling N records with replacement from O i , sample with replacement from O i until there are n = n 0 + n 1 records with the selection event.
Selection status unknown for some participants
In many studies, the selection event S is a dichotomization of a failure-time outcome. For example, in the HIV vaccine example, S is the indicator of HIV-infection during follow-up.
If follow-up varies between participants, one may want to define selection as the occurrence of the selection event (e.g., infection) by time k after randomization. In the HIV vaccine example, one could consider the effect of vaccination on time from infection diagnosis to initiating ART among the subgroup of subjects who would have been infected by time k regardless of treatment assignment. Some subjects may have been censored before time k so their event status at time k is unknown. However, the estimation procedure given in section 3 can be easily extended to account for missing S due to non-informative censoring.
Specifically, re-define S to be the indicator that the event occurred by time k. Those who did not have the event by time k are assigned S = 0 and any subsequent events are ignored, and those who were not followed until time k are censored at the time of their last visit.
Assuming the time until censoring is independent from the time until the selection event, 
Simulations
Primary Simulation Scenarios
To evaluate the performance of our estimators we conducted several simulation experiments. Each simulation generated N data vectors according to the following steps:
1. The first N/2 vectors were set at Z = 0; the second N/2 at Z = 1.
2. For those with Z = z, S was drawn from a Bernoulli(p z ) distribution with p z = 0.10 and 0.05 for z = 0 and 1, respectively.
3. For those with Z = z and S = 1, T was generated from the probability density function
where a = 0.4, b = 9, ψ = 4.08, τ = 24,
The choices for α z were determined by solving the equation 
where I (·) is the indicator function, and accepted T = t if a Bernoulli trial with probability of success = r(t) was a success, otherwise t was discarded. This process was repeated until we accepted some value of t.
4. For those with S = 1, C 1 was generated from a Uniform(0, 100) distribution. Then C was set as min(τ, C 1 ).
5. For all realizations with S = 1, Y was chosen as min(C, T ) and δ = I (Y =T ) .
It can be shown that these steps result in data consistent with SUTVA, (1), (2) For each data generating scenario, we generated 1000 datasets and estimated SCE(t) at intervals were computed using 1000 bootstrap replications: Wald-based confidence intervals (±1.96× standard deviation of 1000 bootstrap estimates of SCE (24)), and percentile-based confidence intervals (2.5th and 97.5th percentiles of the 1000 bootstrap estimates). We also performed simulations for N=5000, varying β 0 and β 1 using all possible 169 [ Figure 2 about here.]
It should be noted that these simulations were set-up to be similar to the HIV vaccine trial, with T in terms of months. Therefore, for example, β 0 = 0.3 corresponds to an odds ratio of exp(0.3 × 12) = exp(3.6) ≈ 36.6 when interpreted in terms of a one-year change (which is how we will scale the odds ratios in section 6).
We performed an additional simulation investigating our method with N = 1000 but higher rates of selection: p 0 = 0.90, p 1 = 0.95, π = 0.89, β 0 = β 1 = −0.1, α 0 = 5.87, and α 1 = 4.08.
Coverage of 95% confidence intervals was 0.955 and 0.959 for percentile and Wald-based intervals, respectively, and bias was small, −0.0008.
Additional Simulation Scenarios
We performed additional simulations under the scenario where a trial is continued until a fixed number of selection events occur (section 4.1). To do this, data were generated in a manner identical to that described above except N was no longer a fixed number and we alternately sampled S from Bernouilli(p 0 ) and Bernouilli(p 1 ) distributions until n = 75, 150, 375, and 750. Simulation results are given in the bottom half of Table 1 and are similar to those where the number of study participants were fixed.
Finally, we performed simulations under the scenario where the selection status was unknown for some participants due to censoring (section 4.2). To do this, data were generated in a manner identical to that described above except step 2 was replaced with the following:
2a. For those with Z = z, the time from randomization to selection, U , was drawn from an exponential distribution with rate parameter λ z , with λ z = −log(1 − p z )/36 and p z = 0.10 and 0.05 for z = 0 and 1, respectively. Hence, P (U 36|Z = z) = p z .
2b. The time from randomization to censoring, C * , was generated from a Uniform(0,100) distribution.
2c. The observed pre-selection follow-up, V , was chosen as min(C * , U ) and the indicator of selection, S * = I (V =U ) . This data generating scenario mimics a study where selection is defined as the selection event occurring within 36 months of randomization, and where some participants are not followed 36 months so their selection event status is unknown. In these simulations, data were generated with N =610, 1220, 3050, and 6100, resulting in approximately n =75, 150, 375, and 750 observed selection events, similar to the other simulations. Results of these simulations are given in the bottom third of Table 1 and are similar to the earlier simulations.
Example
We illustrate our methods using data from a randomized, double-blind, placebo-controlled exposure to drug toxicities, drug resistance, and the depletion of future therapy options. SGL also estimated SCE(t) at t = 2 years but assumed monotonicity (reproduced here as Figure   3 ). Here we repeat the analysis relaxing the assumption of monotonicity.
[ Figure whereas estimates in the light-shaded regions imply that vaccination increased the probability of starting ART by 2 years (was harmful). The sensitivity parameter φ is defined as the probability of infection if randomized to placebo given infection when randomized to vaccine.
φ varies from 0.99, corresponding to a minor departure from monotonicity, to φ =p 0 = 0.094, implying that whether someone gets infected in the vaccine arm is independent of whether they would have been infected if randomized to placebo. This independence assumption seems unlikely; even more unlikely is that S(0) and S(1) are negatively correlated, so plots assuming φ <p 0 are not shown.
[ Figure 4 about here.]
As expected, results when φ = 0.99 closely correspond to the analysis under monotonicity (φ = 1). In both cases, SCE(2) = 0 is rejected for exp(β 0 ) > 1. Under monotonicity, the choice of β 1 is irrelevant; β 1 must be specified when π = 0.99, but its choice has little impact on results. As we get farther away from monotonicity (ie, smaller values of φ), the choice of β 1 has greater impact. Furthermore as φ gets smaller, the range of values for SCE (2) increases. For φ =p 0 , the estimate of SCE (2) Although we have focused our analysis on the difference between the probability of ART initation 2 years after infection diagnosis (SCE(2)), our methods allow estimation of the distribution of the time until ART initiation under vaccine or placebo in the always selected principal stratum, and hence estimates of SCE(t) for any t. Figure 5 shows how estimates of these distributions and SCE(t) change with respect to a few limited choices of the sensitivity parameters. It is challenging to present estimates and confidence intervals from a 3-parameter sensitivity analysis at multiple time points. Such analyses may best be presented with an animation: The supplementary appendix contains an animated sensitivity analysis which shows the estimated SCE(t) in the non-white cohort of the VaxGen trial as a function of the sensitivity parameters for each month post-infection (e.g., for t = 1/12, 2/12, · · · , 24/12).
[ Figure 5 about here.]
Finally, we also performed analyses to estimate SCE(2) where the principal stratum of interest was defined as infection by time k post-randomization regardless of treatment assignment. For k = 36 months, estimates of SCE (2) were very similar to those presented in Figure 4 . That is because 97% of our observed infections occurred by time k = 36 months, and estimates ofp z were quite similar to those where we ignored the length of follow-up.
When k = 24 months, results differed a little more as only 66% of our observed infections had occurred by this time. These analyses are presented in the supplementary appendix.
Discussion
We have described a sensitivity analysis approach for assessing treatment effects on a timeto-event outcome measured in a subset selected after randomization. Our approach extends earlier work by relaxing the monotonicity assumption -that one of the principal strata was empty -and including scenarios where selection status may not be known for some subjects because of censoring. We applied our method to data from an HIV vaccine trial.
Another potential application of these methods is the assessment of a randomized treatment effect in the "per-protocol" sub-population that received the full treatment. For example, it is standard in vaccine efficacy trials to assess the effect of vaccination on timeto-clinically significant infection in the subgroup of subjects who receive all of the protocolscheduled injections (Horne et al., 2000) . However, virtually always in the published literature the analysis assesses the treatment effect in the subgroup of subjects observed to be in the per-protocol population, and hence is susceptible to selection bias. Another relevant example comes from a randomized trial to assess the effect of breast-versus formula-feeding on the composite outcome of HIV infection or death among infants who are alive and HIV-free shortly after birth (Thior et al., 2006) . The purpose of such an analysis is to isolate the effect of breastfeeding versus formula feeding on HIV-free survival, as many infants acquire HIV or die during, before, or shortly after birth. The methods in this article provide approaches for sensitivity analyses to estimate the causal treatment effect in both of these studies.
Our example analysis illustrated the application of the method to a situation where selection (HIV-infection) was rare and the selection rate for one arm was nearly twice that of the other. In these scenarios, results are highly variable across different sensitivity parameters. In contrast, when selection is common (e.g., receiving all protocol-scheduled injections in the example mentioned above), esimates will be less variable across sensitivity parameter values, and relaxing monotonicity will have less impact on the results.
Methods based on principal stratification such as those presented here, are helpful for better understanding causal mechanisms. However, these types of methods are not without limitations. Their utility for decision-making is limited as 1) principal strata membership is almost always unknown, and 2) most decisions regarding treatment use need to take into account both the effect of the treatment on selection as well as the post-selection outcome (Joffe, Small and Hsu, 2007) . For example, licensure of an HIV vaccine will be based on the vaccine's ability to prevent infection, and not just its ability to improve health among those who would get infected regardless of treatment assignment. In addition, principal stratification methods require estimation within discrete strata which may be an oversimplification of the underlying causal mechanisms. For example, infection was treated as a dichotomous outcome, yet a vaccine may affect the timing of infection which then may affect the post-infection outcome. It is conceivable that a vaccine prevents infections from exposure to weak viruses early in a trial, thereby allowing some participants to be infected later in the trial with a more virulent virus. Therefore, although such a participant would be protected by the vaccine, this person would still be in the always infected principal stratum and would have a worse post-infection outcome when assigned vaccine than when assigned placebo (as discussed by Robins, Rotnitzky and Vansteelandt (2007) in a different context).
One could define principal strata based on infection by a specific time from randomization, as presented in this manuscript. However, to fully address this problem one would need to consider many different principal strata which may not be feasible given data sparseness. An such an analysis applied to the VaxGen data. This analysis partially addresses the concern mentioned above because it includes both time to infection and time from infection to starting ART in the outcome. However, because the outcome is comprised of two events, this approach may provide less mechanistic insight. In summary, it should be recognized that even in the principal stratification framework, causal mechanisms may not be readily apparent.
One can also imagine similar scenarios that could lead to violations of the independent censoring assumption (2). For example, those infected earlier with longer potential lengths of post-infection follow-up may be those with weaker immune systems susceptible to more rapid disease progression. This could motivate one to focus on principal strata defined using shorter amounts of time k from randomization until selection. However, in the HIV vaccine trial example, infected subjects were followed a fixed amount of time after infection (2 years), so this potential problem is minimal.
Another challenge to our method is simultaneously specifying and interpreting three sensitivity parameters. Eliciting counterfactual sensitivity parameters can be challenging, and final results, with their caveats and potentially different conclusions at different sensi-tivity parameter values, are usually not amenable to concise statements. One could assign distributions (priors) to our sensitivity parameters and integrate over these parameters to arrive at a single answer. However, because the answer depends on the chosen prior distributions, this approach does not obviate the need for a sensitivity analysis; rather it would be relevant to repeat the analysis for a set of plausible priors, and this set would need to be elicited. We have discussed elicitation and interpretation of sensitivity parameters elsewhere (Shepherd, Gilbert, and Mehrotra 2006) . 
